News, events and videos
News
Calviri Completes Enrollment of 800 Dogs in a Preventative Cancer Vaccine Trial
Calviri, Inc. Announces Formation of Scientific Advisory Board
New generation of cancer-preventing vaccines could wipe out tumors before they form
Preventive cancer vaccine based on neoantigens gets put to the test
Preventive Cancer Vaccine Trial Releases Two-Year Safety Evaluation
Calviri’s Stephen Johnston discusses job opportunities for students
Calviri Appoints Marc Wolff Chief Executive Officer
Calviri Named Most Fundable Company by Pepperdine Graziadio Business School
Calviri Appoints Michael McCallister to Board of Directors
Calviri, Inc. Receives Exclusive Patent License to Immunosignature Technology, Strengthening Its Disease Diagnostic Capabilities
Calviri Appoints Michael Chambers to Board of Directors
Cancer Vaccine Start Up, Calviri, Closes Successful Seed Funding
Calviri Awarded NCI Grant for the Development of a New Blood Test That May Predict Responders to Checkpoint Inhibitor Therapies
Calviri Demonstrates That RNA Processing Errors Are a Rich Source of Tumor Neoantigens for Cancer Vaccines
Cancer Vaccine Developers Report Bumper Crop of New Cancer Antigen
Events
BIO International Convention T
San Diego, California
Attending
Bio-Europe Spring
Basel, Switzerland
Attending
BioTech Showcase (digital)
Virtual
Presenting